Summit Therapeutics Inc. — Director's Dealing 2022

Aug 18, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2022-08-16

Reporting Person: DUGGAN ROBERT W (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-16	Common Stock	P	94849203	$0.97	Acquired	162532792	Direct

Footnotes

F1: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering.